.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA23_Delafloxacin.Delafloxacin

Information

Delafloxacin is a fluoroquinolone antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) in adults. It is active against a broad range of Gram-positive and Gram-negative bacteria, including MRSA.

Pharmacokinetics

Population pharmacokinetic model for healthy adult subjects and infected patients, both male and female, aged 18–85 years; values represent typical PK after a single 300 mg intravenous infusion or 450 mg oral dose. Oral PK represents fasted state.

References

1. Lv, J-X, et al., & Su, Y-W (2024). Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization. Antimicrobial agents and chemotherapy 68(7) e0042824–None. DOI:10.1128/aac.00428-24 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38899925

Revisions

• 06/2025 initial generated model